Professional Documents
Culture Documents
Content
Outcomes
Band
MGP-5
1-2
MG2H-5
1-2
MGP-3
1-2
MG2H6
2-3
MGP-6
2-3
MG2H-2
1-2
MGP-6
2-3
MG2H-3
3-4
FSDr3: Safety
MGP-3
3-4
10
MG2H-2
4-5
11
MG2H-6
2-3
12
FSHe2: Medication
MG2H-3
2-3
13
MG2H-3
3-4
14
MG2H-8
2-3
15
MG2H-4
3-4
16
MG2H-6
3-4
17
MG2H-4
3-4
18
MG2H-7
4-5
19
MG2H-7
3-4
20
MG2H-5
5-6
21
MG2H-5
3-4
22
MG2H-5
4-5
23
MG2H-3
5-6
24
MG2H-8
3-4
25
MG2H-6
4-5
Section II
Questio
n
Mark
26(a)
26(b) (i)
Content
Outcomes
Band
MG2H-3
1-2
MG2H-5
1-2
26(b) (ii)
MG2H-5
2-3
26(c) (i)
MG2H-5
2-3
26(c) (ii)
MG2H-5
1-2
26(d) (i)
MG2H-6
2-3
26(d) (ii)
MG2H-6
3-4
26(e) (i)
MG2H-8
1-2
26(e) (ii)
MG2H-8
2-3
26(f) (i)
MGP-6
2-3
26(f) (ii)
MGP-6
3-4
27(a)
MG2H-7
2-3
27(b)
MG2H-3
4-5
27(c) (i)
MGP-3
2-3
27(c) (ii)
MGP-3
2-3
27(d)
MG2H6
1-2
27(e) (i)
MG2H-7
4-5
27(e) (ii)
MG2H-7
4-5
27(e)(iii)
MG2H-7
4-5
27(e) (iv)
MG2H-7
1-2
27(f)
FSHe2: Medication
MG2H-3
2-3
28 (a) (i)
MG2H-3
1-2
28 (a) (ii)
MG2H-3
3-4
28(a)(iii)
MG2H-3
3-4
28(b) (i)
MG2H-3
4-5
28(b) (ii)
MG2H-3
5-6
28(c)
MG2H-7
3-4
28(d) (i)
MG2H-8
3-4
28(d) (ii)
MG2H-8
3-4
28(e) (i)
MG2H-5
3-4
28(e) (ii)
MG2H-5
2-3
29 (a) (i)
MG2H-4
3-4
29 (a) (ii)
MG2H-4
3-4
29(a)(iii)
MG2H-4
4-5
29(a)(iv)
MG2H-4
5-6
29(b)
MGP-6
2-3
29(c) (i)
MG2H-4
2-3
29(c) (ii)
MG2H-4
3-4
29(c)(iii)
MG2H-4
3-4
29(c) (iv)
MG2H-4
4-5
29(d)
FSDr3: Safety
MGP-3
3-4
29(e)
MG2H-3
2-3
30(a) (i)
MG2H-6
1-2
30(a) (ii)
MG2H-6
2-3
30(a)(iii)
MG2H-6
2-3
30(a) (iv)
MG2H-6
2-3
30(b)
MG2H-3
5-6
30(c) (i)
MG2H-2
3-4
30(c) (ii)
MG2H-2
3-4
30(c)(iii)
MG2H-2
3-4
30(c) (iv)
MG2H-2
3-4
30(d) (i)
MG2H-6
3-4
30(d) (ii)
MG2H-6
4-5
30(d)(iii)
MG2H-6
4-5